Chronic myeloid leukemia: Reminiscences and dreams

Haematologica

Volumn 101, Issue 5, 2016, Pages 541-558

  Mughal, Tariq I ^a   Radich, Jerald P ^b   Deininger, Michael W ^c   Apperley, Jane F ^d   Hughes, Timothy P ^e   Harrison, Christine J ^f   Gambacorti Passerini, Carlo ^g   Saglio, Giuseppe ^h   Cortes, Jorge ⁱ   Daley, George Q ^j  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d HAMMERSMITH HOSPITAL   (United Kingdom)

^e UNIVERSITY OF ADELAIDE   (Australia)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g UNIVERSITY OF MILANO BICOCCA   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j BOSTON CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABL1 TYROSINE KINASE INHIBITOR; BOSUTINIB; BUSULFAN; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; PROTEIN KINASE INHIBITOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL (TOPIC); CYTOGENETICS; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; HUMAN; IRRADIATION; LEUKEMOGENESIS; MOLECULAR BIOLOGY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHILADELPHIA 1 CHROMOSOME; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; ART; CHEMISTRY; CHROMOSOME ANALYSIS; GENETICS; HISTORY; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULARLY TARGETED THERAPY; MORTALITY; MUTATION; PROCEDURES; PROGNOSIS; RESEARCH;

ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; FUSION PROTEINS, BCR-ABL; HISTORY, 20TH CENTURY; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR TARGETED THERAPY; MUTATION; PHILADELPHIA CHROMOSOME; PROGNOSIS; PROTEIN KINASE INHIBITORS; RESEARCH;

EID: 84964777739     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.139337     Document Type: Review

References (201)

1. Ben-Neriah Y, Daley GQ, Mes-Masson AM, et al. The chronic myelogenous leukemiaspecific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986;233 (4760):212-214.
2. Goldman JM. Melo JV. Targeting the BCRABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1084-1086.
3. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561-566.
4. Druker BJ, Guilhot F, O’Brien SG, et al. Fiveyear Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. N Engl J Med. 2006;355(23):2408-2417.
5. Kantarjian H, Cortes JE. Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia. J Clin Oncol. 2014;32 (27):3077.
6. Huang XL, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012;118(12): 3123-3127.
7. Mughal TI, Cortes J, Cross NCP, et al. Chronic myeloid leukemia – some topical issues. Leukemia. 2007;21(7):1347-1352.
8. Falchi L, Kantarjian HM, Wang X, et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013;88 (12):1024-1029.
9. Mughal TI, Goldman JM. An essay in cancer medicine: Lessons learned from patients with chronic myeloid leukaemia. Clin Med. 2005;1:2-7.
10. Cheah CY, Burbury K, Apperley JF, et al. Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable longterm remissions with imatinib. Blood. 2014;123(23):3574-3577.
11. Velpeau A. [Sur la resorption du puseat sur l’alteration du sang dans les maladies Clinique de persection nenemant.] Premier observation. Rev Med. 1827;2:216.
12. Bennett JH. Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood. Edinb Med Surg J. 1845;64:413-423.
13. Virchow R. [Weisses Blut]. Froriep’s Notzien 1845;36:151-156.
14. Tjio JH, Levan A. The chromosome number of man. Hereditas. 1956;42:1-6.
15. Lejeune J, Turpin R, Gautier M. [Chromosomic diagnosis of mongolism]. Archives Francaises de Pediatrie. 1959;16: 962-963.
16. Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science. 1960;132:1497.
17. Baikie AG, Court-Brown WM, Buckton KE, Harnden DG, Jacobs PA, Tough IM. A possible specific chromosome abnormality in human chronic myeloid leukaemia. Nature. 1960;188:1165-1166.
18. Boveri T. [Frage der Entstehung maligner Tumoren.] Jena: Gustav Fischer;1914.
19. Fialkow PJ, Garler SM, Yoshida A. Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA. 1967;58(4): 1468-1471.
20. Ohno S, Makino S. The single X-nature of sex chromatin in man. Lancet. 1961;1 (7168):78-79.
21. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290-293.
22. Abelson HT, Rabstein LS. Lymphosarcoma: virus-induced thymic-independent disease in mice. Cancer Res. 1970;30(8):2213-2222.
23. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell. 1984;36(1):93-99.
24. Heisterkamp N, Groffen J, Stephenson JR, et al. Chromosomal localization of human cellular homologues of two viral oncogenes. Nature. 1982;299(5885):747-749.
25. de Klein A, van Kessel AG, Grosveld G, et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1982;300(5894): 765-767.
26. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306(5940):277-280.
27. Stam K, Heisterkamp N, Grosveld G, et al. Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome. N Engl J Med. 1985;313(23):1429-1433.
28. Shtivelman E, Lifshitz B, Gale RP, et al. Alternative splicing of RNAs transcribed from the human abl gene and from the bcrabl fused gene. Cell. 1986;47(2):277-284.
29. Witte ON, Dasgupta A, Baltimore D. Abelson murine leukaemia virus rotein is phosphorylated in vitro to form phosphotyrosine. Nature. 1980;283(5750):826-831.
30. Prywes R, Foulkes JG, Baltimore D. The minimum transforming region of v-abl is the segment encoding protein-tyrosine kinase. J Virol. 1985;54(1):114-122.
31. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell. 1984;37(3): 1035-1042.
32. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoetic cell line by chronic myelogenous leukemiaspecific P210 bcr/abl protein. Proc Natl Acad Science. 1988;85(23):9312-9316.
33. Lugo TG, Pendergast AM, Muller AJ, et al. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247(4946):1079-1082.
34. Daley GQ, van Etten, Baltimore D. Induction of chronic myelogenous leukemia in mice by P210 BCR/ABL gene of the Philadelphia chromosome. Science. 1990; 247(4944):824-830.
35. Elephanty AG, Hariharan IK, Cory S. Bcrabl, the hallmark of chronic myeloid leukeima in man, induces multiple hemopoietic neoplasms in mice. EMBO J. 1990;9(4):1069-1078.
36. Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a Chrnic myeloid leukemia-like Syndrome in Mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA. 1990;87(17):6649-6653.
37. Anafi M, Gazit A, Gilon C, et al. Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins. J Biol Chem. 1992;267(7):4518-4523.
38. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992; 70(6):901-910.
39. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75(1):175-185.
40. Neshat MS, Raitano AB, Wang HG, et al. The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and-independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol. 2000;20(4):1179-1186.
41. Sillaber C, Gesbert F, Frank DA, et al. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood. 2000;95(6):2118-2125.
42. Salgia R, Sattler M, Pisick E, et al. p210BCR/ABL induces formation of complexes containing focal adhesion proteins and the protooncogene product p120c-Cbl. Exp Hematol. 1996;24(2):310-313.
43. Sattler M, Mohi MG, Pride YB, et al. Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell. 2002;1(5):479-492.
44. Zhao C, Blum J, Chen A, et al. Loss of betacatenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007;12(6):528-541.
45. Dierks C, Beigi R, Guo GR, et al. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell. 2008;14(3):238-249.
46. Neviani P, Harb JG, Oaks JJ, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest. 2013;123(10):4144-4157.
47. Hurtz C, Hatzi K, Cerchietti L, et al. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med. 2011;208 (11):2163-2174.
48. Chen Y, Hu Y, Zhang H, et al. Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet. 2009;41(7):783-792.
49. O'Hare T, Zabriskie MS, Eiring AM, et al. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer. 2012;12(8):513-526.
50. Corbin AS, Agarwal A, Loriaux M, et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2011;121(1):396-409.
51. Mughal T, Goldman J. Chronic myeloid leukemia: a historical perspective. In: Mughal T, Goldman J, (eds.) Chronic Myeloproliferative Disorders. Paul Street, London: Informa Healthcare 2008: pp1-16.
52. Dalton DAG. Myelran in chronic myeloid leukaemia. Lancet. 1953;1:208.
53. Kennedy BJ, Yarbo JW. Metabolic and therapeutic effects of hydroxyurea in chronic myelogenous leukemia. Trans Assoc Am Physicians. 1965;78:391-399.
54. Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood. 1993;82(2):398-407.
55. Talpaz M, Kantarjian H, McCredie K, et al. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia. N Engl J Med. 1986;314 (17):1065-1069.
56. Hehlmann R, Heimpel H, Hasford J, et al; on behalf of the German CML Study Group. Randomized comparison of interferon-alpha with busulphan and hydroxyurea in chronic myelogenous leukemia. Blood. 1994;84(12):4064-4077.
57. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med. 1994; 330(12):820-825.
58. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randimised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council’s Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 1995;345(8962): 1392-1397.
59. Guilhot F, Chastang C, Michallet M, et al; on behalf of the French Chronic Myeloid Leukemia Study Group. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med. 1997;337(4):223-329.
60. Silver RT, Woolf SH, Hehlmann R, et al. An evidence-based analysis of the effect of busulfan, hydoxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999;94(5):1517-1536.
61. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037.
62. Mughal TI, Goldman JM. Chronic myeloid leukaemia: A therapeutic challenge. Ann Oncol. 1995;6(7):637-644.
63. Mughal TI, Goldman JM. Chronic Myeloid leukemia: Current Status and Controversies. Oncology (Williston Park). 2004;18(7):837-847.
64. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63(4):789-799.
65. Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukaemia treated with interferon alpha. J Natl Cancer Inst. 1998;90(11):850-858.
66. Hoffman VS, Baccarani M, Lindoerfer D, et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia. 2013;27(10):2016-2022.
67. Mughal TI, Barbui T, Abdel-Wahab O, et al. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. Leuk Lymphoma. 2015;56(7):1938-1948.
68. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest. 2000;105(1):3-7.
69. Deininger MW, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105(7):2640-2653.
70. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645-652.
71. Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 2008;111(3):1039-1043.
72. Deininger MW, O’Brien SG, Guilhot F, et al. International Randomized Study of Interferon vs STI571 (IRIS) 8 years Followup: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase Treated with Imatinib. ASH Annual Meeting Abstracts 2009;114:1126-.
73. Baccarani M, Soverini S. Molecular Response in CML: Where is the bar? Blood. 2014;124(4):469-471.
74. Mughal TI, Vannucchi AM, Soverini S, et al. Preclinical and clinical issues in chronic myeloproliferative neoplasms. Haematologica. 2014;99(5):797-801.
75. Kantarjian H, O’Brien S, Jabbour E, et al. Improved survival in chronic myeloid leukemia since the introduction of imatinib: a single-institution historical experience. Blood. 2012;119(9):1981-1987.
76. Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosomepositive chronic phase chronic myeloid leukemia. Blood. 2004;103(8):2873-2878.
77. Cortes JE, Kantarjian HM, Goldberg SL, et al. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol. 2009;27(28): 4754-4759.
78. Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized. Open-label study of daily imatinib mesylate 400mg versus 800mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol. 2010;28(3):424-430.
79. Hehlmann R, Muller MC, Lauseker M, et al. Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV. J Clin Oncol. 2014;32(5):415-423.
80. Proetel U, Pletsch N, Lauseker M, et al. Older patients with chronic myeloid leukemia (>65 years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. Ann Hematol. 2014;93(7):1167-1176.
81. Deininger MW, Kopecky KJ, Radich JP, et al. Imatinib 800mg daily induces deeper molecular responses than imatinib 400mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. Br J Haematol. 2014;164(2):223-232.
82. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010;363(26):2511-2521.
83. Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Nat Cancer Inst. 2011;103(7):553-561.
84. Mughal TI, Schreiber A. Long term toxicity of imatinib when used as a first-line therapy in chronic myeloid leukemia. Biologics. 2010;4:315-323.
85. Efficace F, Baccarani M, Breccia M, et al. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013;27(7):1511-1519.
86. Gambacorti-Passerini C, Tornaghi L, Cavagnini F, et al. Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet. 2003;361(9373):1954-1956.
87. Verma D, Kantarjian H, Strom SS, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011;118(16): 4353-4358.
88. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26(20):3358-3363.
89. Lucas CM, Wang L, Austin GM, et al. A population study of imatinib in chronic myeloid leukemia demonstrates lower efficacy than in clinical trials. Leukemia. 2008;22(10): 1963-1966.
90. Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385(9976):1447-1459.
91. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876-680.
92. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukemia. Lancet Oncol. 2007;8(11):1018-1029.
93. Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at risk of disease progression. J Clin Oncol. 2008;26(29):4806-4813.
94. Soverini S, Branford S, Nicolini FE, et al. Implications of BCR-ABL1 kinase domainmediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38(1):10-20.
95. Eiring AM, Deininger MW. Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia. Genome Biol. 2014;15(9):461.
96. Watkins DB, Hughes TP, White DL. OCT1 and imatinib transport in CML: is it clinically relevant? Leukemia. 2015;29(10):1960-1969.
97. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007;110(8):2828-2837.
98. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129-141.
99. Bradeen HA, Eide CA, O’Hare T, et al. Comparison of imatinib mesylate, dasatinib (BM-354825) and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108(7):2332-2338.
100. Tokarski JS, Newitt JA, Chang CYJ, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resitant ABL mutants. Cancer Res. 2006;66(11):5790-5797.
101. Schittenhelm MM, Shiraga S, Schroeder A, et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 2006;66(1):473-481.
102. Milojkovic D, Apperley JF, Gerrad G, et al. Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood. 2012;119(8):1838-1843.
103. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542-2551.
104. Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinibintolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 2013;27(1):107-112.
105. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354(24):2531-2541.
106. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008;22(6):1200-1206.
107. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib with dasatinib 100mg once daily preserves efficacy and improves toerability in imatinib-resistant and – intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008;26(19):3204-3212.
108. Shah NP, Guilhot F, Cortres JE, et al. Longterm outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. Blood. 2014;123(15):2317-2324.
109. Brümmendorf TH, Shah NP, Cortes JE, et al. Long-term efficacy and safety of dasatinib 100mg once daily (QD) in patients with imatinib resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP): 5-year folow-up from CA180-034. Onkologie. 2011;34:263.
110. Müller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009;114(24):4944-4953.
111. Le Coutre P, Rea D, Abruzzese E, et al. Severe peripheral arterial disease during nilotinib therapy. J Natl Cancer Inst. 2011;103(17):1347-1348.
112. Assouline S, Laneuville P, Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med. 2006;354 (24):2623-2624.
113. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic mye;loid leukemia. N Engl J Med. 2010;362(24):2251-2259.
114. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260-2270.
115. Larson RA, Hochhaus A, Clark RE, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia. 2012;26(10):2197-2203.
116. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014;123(4):494-500.
117. Tefferi A. Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified? Leukemia. 2013;27(9):1939-1940.
118. Giles FJ, Mauro MJ, Hong F, et al. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. Leukemia. 2013;27(6):1310-1315.
119. Montani D, Bergot E, Gunther S, et al. Pulmonary arterial hypertension in patients treated with dasatinib. Circulation. 2012;125(17):2128-2137.
120. Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100mg versus imatinib 400mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 2012;120(19):3898-3905.
121. Hughes TP, Saglio G, Kantarjian HM, et al. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 2014;123(9):494-500.
122. Hughes TP, Lipton JH, Spector N, et al. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 2014;124(5):729-736.
123. Remsing LL, Rix U, Colinge J, et al. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid cells. Leukemia. 2009;23(3):477-480.
124. Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011;118(17):4567-4576.
125. Kantarjian HM, Cortes JE, Kim DW, et al. Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood. 2014;123(9):1309-1318.
126. Gambacorti-Passerini C, Brummendorf TH, Kim DW, et al. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: minimum 24-month follow-up. Am J Hematol. 2014;89(7):732-742.
127. Lipton JH, Cortes JE, Khoury HJ, et al. Longterm bosutinib in patients with chronic phase chronic myeloid leukemia after prior imatiniib failure. J Clin Oncol. 2015;33(15): 7076.
128. Brümmendorf TH, Cortes JE, de Souza CA, et al. Bosutinib versus imatinib in newly diagnsoed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haemtol. 2015;168(1):69-81.
129. O’Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potentially inhibits the T315I mutant and overcomemutation-based resistance. Cancer Cell. 2009; 16(5):401-412.
130. Goldman JM. Ponatinib for Chronic Myeloid Leukemia. N Engl J Med 2012; 367(22):2148-2149.
131. Lierman E, Smits S, Cools J, et al. Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases. Leukemia. 2012;26(7):1693-1695.
132. Zabriskie M, Eide CA, Tantravahisk, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosomepositive leukemia. Cancer Cell. 2014;26(3): 428-442.
133. Deininger MW, Hodgson JG, Shah NP, et al. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. 2015 Nov 24. [Epub ahead of print]
134. Cortes JE, Kantarjian HM, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22):2075-2088.
135. Cortes JE, Kim D-W, Pinella-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783-1796.
136. Neelkantan P, Marin D, Laffan M, et al. Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for CML resistant to multiple tyrosine kinase inhibitor therapy. Haematologica. 2012;97(9):1444.
137. Lipton JH, Chuah C, Guerci-Bresler A, et al. EPIC: A phase III trial of ponatinib (PON) versus imatinib (IM) in patients with newly diagnosed CR-CML. Blood. 2014;124(21): 519.
138. Gandhi V, Plunkett W, Cortes JE, et al. Omacetaxine: A protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014;20(7):1735-1740.
139. Yun SM, Jung KH, Kim SJ, et al. HS-438, a new inhibitor of imatinib-resistant BCRABL T315I mutation in chronic myeloid leukemia. Cancer Lett. 2014;348(1-2):50-60.
140. Mughal TI, Kavita R. Port-wine flavoured sandwiches and haematopoetic stem cell transplantation. Lancet Oncology. 2009;10 (9):926.
141. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med. 2007; 357(15):1472-1475.
142. Mughal T. Chronic leukemias. Classic papers in Hematologic Malignancies. Ed Thomas, Nathan, Goldman. Pub: Taylor Francis, London and New York. 2001;139-44.
143. Goldman JM, Catovsky D, Galton DA. Reversal of blast-cell crisis in C.G.L. by transfusion of stored autologous buffy-coat cells. Lancet. 1978;1(8061):437-438.
144. Goldman JM, Baughan AS, McCarthy DM, et al. Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia. Lancet. 1982;2(8299):623-625.
145. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338(14):962-968.
146. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989;321(17):1174-1178.
147. Goldman JM, Apperley JF, Jones L, et al. Bone Marrow Transplantation for patients with Chronic Myeloid Leukemia. N Engl J Med. 1986;314(4):202-207.
148. Apperley JF, Jones J, Hale G, et al. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graftversus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant. 1986;1(1):53-66.
149. Innes AJ, Milojkovic D, Apperley JF. Allogeneic transplantation for CML in the TKI era: striking the right balance. Nat Rev Clin Oncol. 2015 Nov 17 [Epub ahead of print]
150. Kolb HJ, Mittermüller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462-2465.
151. McKinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evalutaing escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995; 86(4):1261-1268.
152. Gratwohl A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet. 1998;352 (9134):1087-1082.
153. Crawley C, Szydlo R, Lalancette M, et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005;106(9):2969-2976.
154. Mughal TI, Yong A, Szydlo R, et al. The probability of long-term leukemia free survival for patients in molecular remission 5 years after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase. Br J Haematol. 2001;115(3):569-574.
155. Radich JP, Gooley T, Bryant E et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation. Blood. 2001;98(6):1701-1707.
156. Sauselle S, Lauseker M, Gratwohl A, et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood. 2010;115(10):1880-1885.
157. Oyekunle A, Zander A, Binder M, et al. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Ann Hematol. 2013;92(4):487-496.
158. Jabbour E, Cortes JE, Santos FP, et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood. 2011;117(13):3641-3647.
159. Jain NA, Ito S, Tian X, et al. Clinical and biological predictors of outcome following relapse of CML post-allo-SCT. Bone Marrow Transplant. 2015;50(8):1138-1140.
160. Shimoni A, Volchek Y, Koren-Michowitz M, et al. Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121(6):863-871.
161. O’Brien S, Abboud CN, Akhtari M, et al. Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia, Version 3. National Comprehensive Cancer Network. [Last accessed June 2 2014].
162. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99(10):3530-3539.
163. Apperley JF, Cortes JE, Kim DW, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START-A trial. J Clin Oncol. 2009;27(21):3472-3479.
164. Bjorkholm M, Ohm L, Eloranta S, et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol. 2011;29(18):2514-2520.
165. Gallipoli P, Abraham SA, Holyoake TL. Hurdles Toward a Cure for CML: The CML Stem Cell. Hematol Oncol Clin North Am. 2011;25(5):951-966.
166. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood. 2006;107(11):4532-4539.
167. CML Experts. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013;121(22):4439-4442.
168. Mahon F, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.
169. Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515-522.
170. Branford S, Yeung DT, Ross DM, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 2013;121(19): 3818-3824.
171. Ahmed W, van Etten RA. Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosinekinase inhibitor combinations and beyond. Hematology Am Soc Hematol Educ Program. 2013;2013:189-200.
172. O’Hare T, Zabriske MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukemia. Nat Rev Cancer. 2012;12(8):513-526.
173. Bhatia R. Altered microenvironment regulation of CML stem cells. Leuk Supplements. 2014;S1-S2.
174. Gallipoli P, Cook A, Rhodes S, et al. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of chronic phase CML CD34+ cells in vitro and in vivo. Blood 2014;124(9):1492-1501.
175. Zhang B, Ho YW, Maeda T, et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012;21(4):577-592.
176. Weisberg E, Azab AK, Manley PW, et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia. 2012;26(5):985-990.
177. Krause DS, Scadden DT. A hostel for the hostile: the bone marrow niche in hematologic neoplasms. Haematologica. 2015;100(11):1376-1387.
178. Kawasaki ES, Clark SS, Coyne MY, et al. Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA. 1988;85(15):5698-5702.
179. Sawyers CL, Timpson L, Kawasaki ES, Clark SS, Witte ON, Champlin R. Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction. Proc Natl Acad Sci. 1990;87(2):563-567.
180. Hughes TP, Morgan GJ, Martiat P, Goldman JM. Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse. Blood. 1991;77(4):874-878.
181. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993;82(6): 1929-1936.
182. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCRABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37.
183. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423-1432.
184. Cross NCP, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia. 2012;26(10):2172-2175.
185. Cross NCP, White HE, Colomer D, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia 2015;29(5):999-1003.
186. Winn-Deen ES, Helton B, Van Atta R, et al. Development of an integrated assay for detection of Bcr-Abl RNA. Clin Chem. 2007;53(9):1593-1600.
187. Oehler VG, Wuin J, Ramakrishnan R, et al. Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR. Leukemia. 2009;23(2):396-399.
188. Ross D, Branford S, Seymour JF, et al. Patients with chronic myeloid leukemia who maintain a complete molecular remission after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR Leukemia. 2010;24(10):1719-1724.
189. LaBarre P, Hawkins KR, Gerlach J, et al. A simple, inexpensive device for nucleic acid amplification without electricity-toward instrument-free molecular diagnostics in low-resource settings. PLoS One. 2011;6(5): e19738.
190. Soverini S, Hochhaus A, Nicolini FE, et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5): 1208-1215.
191. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet Recommendations for the management of Chronic Myeloid Leukemia. Blood. 2013;122(6):872-884.
192. San-Miguel JF, Kantarjian HM. Improved understanding of disease biology and treatment: Multiple Myeloma and Chronic Myeloid Leukaemias in 2014. Nat Rev Clin Oncol. 2015;12(2):71-72.
193. Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and >10%BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124(4):511-518.
194. Branford S, Roberts N, Yeung DT, et al. Any BCR-ABL reduction below 10% at 6 months of therapy significantly improves outcome for CML patients with a poor response at 3 months. Blood. 2013;122(21): (Abstract 254).
195. Kim DD, Hamad N, Lee HG, et al. BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase. Am J Hematol. 2014;89(6):626-632.
196. Neelakantan P, Gerrad C, Lucas C, et al. Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies. Blood. 2013;121(14):2739-2742.
197. The Lancet Haematology. Chronic myeloid Leukaemia: time to push for a cure? Lancet. 2015;2(5):e175.
198. Mathisen MS, Kantarjian HM, Cortes JE, Jabbour E. Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Rev. 2014;28(5):179-187.
199. Holyoake TL, Helgason GV. Do we need more drugs for CML? Immunol Rev. 2015;263(1):106-123.
200. Etienne G, Dulucq S, Lascaux A, et al. ELN 2013 response status criteria: Relevance for de novo imatinib chronic phase chronic myelpoid leukemia patients? Am J Hematol. 2015;90(1):37-41.
201. Ross TS, Mgbemena VE. Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia. Mol Cell Oncol. 2014;1(3): e963450.